Characterising the phenotypic evolution of circulating tumour cells during treatment

Real-time monitoring of cancer cells’ phenotypic evolution during therapy can provide vital tumour biology information for treatment management. Circulating tumour cell (CTC) analysis has emerged as a useful monitoring tool, but its routine usage is restricted by either limited multiplexing capability or sensitivity. Here, we demonstrate the use of antibody-conjugated and Raman reporter-coated gold nanoparticles for simultaneous labelling and monitoring of multiple CTC surface markers (named as “cell signature”), without the need for isolating individual CTCs. We observe cell heterogeneity and phenotypic changes of melanoma cell lines during molecular targeted treatment. Furthermore, we follow the CTC signature changes of 10 stage-IV melanoma patients receiving immunological or molecular targeted therapies. Our technique maps the phenotypic evolution of patient CTCs sensitively and rapidly, and shows drug-resistant clones having different CTC signatures of potential clinical value. We believe our proposed method is of general interest in the CTC relevant research and translation fields.Monitoring the heterogeneity of circulating tumour cells (CTCs) and their phenotypic changes during treatment is a challenge. This study describes and tests a method for detection and quantitative heterogeneity analysis of melanoma CTCs in 10 stage-IV melanoma patients.

[1]  Ximei Qian,et al.  Detection of circulating tumor cells in human peripheral blood using surface-enhanced Raman scattering nanoparticles. , 2011, Cancer research.

[2]  Irving L. Weissman,et al.  Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271 , 2011, Nature.

[3]  M. Aurrand-Lions,et al.  CD146 Expression in Human Breast Cancer Cell Lines Induces Phenotypic and Functional Changes Observed in Epithelial to Mesenchymal Transition , 2012, PloS one.

[4]  James B. Freeman,et al.  Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells , 2012, Journal of Translational Medicine.

[5]  G. Frens.  Controlled Nucleation for the Regulation of the Particle Size in Monodisperse Gold Suspensions , 1973 .

[6]  D. Morton,et al.  mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads. , 2009, Clinical chemistry.

[7]  S. Ferrone,et al.  Functional and clinical relevance of chondroitin sulfate proteoglycan 4. , 2010, Advances in cancer research.

[8]  M. Millward,et al.  Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment , 2015, The Journal of investigative dermatology.

[9]  Carlos Caldas,et al.  The implications of clonal genome evolution for cancer medicine. , 2013, The New England journal of medicine.

[10]  P. Rothberg,et al.  ERBB3 is required for metastasis formation of melanoma cells , 2014, Oncogenesis.

[11]  M. Bar‐eli,et al.  Role of AP-2 in Tumor Growth and Metastasis of Human Melanoma , 2004, Cancer and Metastasis Reviews.

[12]  G. Parker,et al.  Imaging Intratumor Heterogeneity: Role in Therapy Response, Resistance, and Clinical Outcome , 2014, Clinical Cancer Research.

[13]  O. Parolini,et al.  Isolation and characterization of mesenchymal cells from human fetal membranes , 2007, Journal of tissue engineering and regenerative medicine.

[14]  S. Digumarthy,et al.  Isolation of rare circulating tumour cells in cancer patients by microchip technology , 2007, Nature.

[15]  Brigitte Rack,et al.  Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System , 2007, Clinical Cancer Research.

[16]  Álvaro González,et al.  Evaluation of multiple serum markers in advanced melanoma , 2011, Tumor Biology.

[17]  Johannes G. Reiter,et al.  The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers , 2012, Nature.

[18]  Sebastian Schlücker,et al.  SERS microscopy: nanoparticle probes and biomedical applications. , 2009, Chemphyschem : a European journal of chemical physics and physical chemistry.

[19]  J. Nieva,et al.  Case study of the morphologic variation of circulating tumor cells. , 2007, Human pathology.

[20]  H. Maecker,et al.  Mass cytometry: protocol for daily tuning and running cell samples on a CyTOF mass cytometer. , 2012, Journal of visualized experiments : JoVE.

[21]  Mehmet Toner,et al.  Inertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor Cells , 2013, Science Translational Medicine.

[22]  C. Gedye,et al.  The Ludwig Institute for Cancer Research Melbourne Melanoma Cell Line Panel , 2013, Pigment cell & melanoma research.

[23]  Sridhar Ramaswamy,et al.  Isolation and molecular characterization of circulating melanoma cells. , 2014, Cell reports.

[24]  R. Álvarez-Puebla,et al.  Universal One-Pot and Scalable Synthesis of SERS Encoded Nanoparticles , 2015 .

[25]  D. Garrison,et al.  Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  S. Nie,et al.  Novel surface-enhanced Raman scattering-based assays for ultra-sensitive detection of human pluripotent stem cells. , 2016, Biomaterials.

[27]  M. Sliwkowski,et al.  Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells , 1999, Oncogene.

[28]  G. Argenziano,et al.  CD271 is expressed in melanomas with more aggressive behaviour, with correlation of characteristic morphology by in vivo reflectance confocal microscopy , 2015, The British journal of dermatology.

[29]  Shui-Tong Lee,et al.  Reversible and Precise Self-Assembly of Janus Metal-Organosilica Nanoparticles through a Linker-Free Approach. , 2016, ACS nano.

[30]  Klaus Pantel,et al.  Biology, detection, and clinical implications of circulating tumor cells , 2014, EMBO molecular medicine.

[31]  H. Moch,et al.  Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. , 2011, Cancer research.

[32]  Jean Salamero,et al.  Microfluidic sorting and multimodal typing of cancer cells in self-assembled magnetic arrays , 2010, Proceedings of the National Academy of Sciences.

[33]  S. Ferrone,et al.  Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. , 2004, Critical reviews in immunology.

[34]  P. Lorigan,et al.  Circulating tumour cells as tumour biomarkers in melanoma: detection methods and clinical relevance. , 2015, Annals of Oncology.

[35]  Qiang Li,et al.  Building Electromagnetic Hot Spots in Living Cells via Target-Triggered Nanoparticle Dimerization. , 2017, ACS nano.

[36]  Steven R. Emory,et al.  Probing Single Molecules and Single Nanoparticles by Surface-Enhanced Raman Scattering , 1997, Science.

[37]  Jonathan W. Uhr,et al.  Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases , 2004, Clinical Cancer Research.

[38]  A. Aplin,et al.  Function-blocking ERBB3 antibody inhibits the adaptive response to RAF inhibitor. , 2014, Cancer research.

[39]  M. Rojewski,et al.  Phenotypic Characterization of Mesenchymal Stem Cells from Various Tissues , 2008, Transfusion Medicine and Hemotherapy.

[40]  K. Pantel,et al.  Challenges in circulating tumour cell research , 2014, Nature Reviews Cancer.

[41]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[42]  F. Bertucci,et al.  CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines , 2009, Breast Cancer Research.

[43]  G. Fierlbeck,et al.  Circulating tumor cells and detection of the melanoma-associated antigen HMW-MAA in the serum of melanoma patients. , 2006, The Journal of investigative dermatology.

[44]  Levi A Garraway,et al.  Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de‐differentiated state , 2017, Molecular systems biology.

[45]  D. Massi,et al.  Circulating Tumor Cells in Cutaneous Melanoma , 2011 .

[46]  J. Lehmann,et al.  Discrimination between benign and malignant cells of melanocytic lineage by two novel antigens, a glycoprotein with a molecular weight of 113,000 and a protein with a molecular weight of 76,000. , 1987, Cancer research.

[47]  J. Landsberg,et al.  Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation , 2012, Nature.

[48]  Caroline Dive,et al.  Molecular analysis of circulating tumour cells—biology and biomarkers , 2014, Nature Reviews Clinical Oncology.

[49]  P. Hersey,et al.  Polymerase chain reaction detection of melanoma cells in the circulation: relation to clinical stage, surgical treatment, and recurrence from melanoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  M. Bar‐eli,et al.  Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8. , 2006, Pigment cell research.

[51]  Marcin Wojdyr,et al.  Fityk: a general-purpose peak fitting program , 2010 .

[52]  Jason B. Lee,et al.  Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. , 2013, The Journal of clinical investigation.

[53]  R. Weinberg,et al.  EMT, CSCs, and drug resistance: the mechanistic link and clinical implications , 2017, Nature Reviews Clinical Oncology.

[54]  S. Iacobelli,et al.  Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines , 2015, Oncotarget.

[55]  Mark M Davis,et al.  Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device , 2009, Proceedings of the National Academy of Sciences.

[56]  R. Dasari,et al.  Single Molecule Detection Using Surface-Enhanced Raman Scattering (SERS) , 1997 .

[57]  F. Marincola,et al.  The immune score as a new possible approach for the classification of cancer , 2012, Journal of Translational Medicine.

[58]  L. Fattore,et al.  Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma , 2015, Oncotarget.

[59]  W. Barry,et al.  CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. , 2010, Journal of the National Cancer Institute.